Premium
Palladium causes bizarre skin hyperpigmentation in long‐term dihydrocodeinone ‘Braun’ abusers
Author(s) -
Arenbergerova M.,
Arenberger P.,
Gkalpakiotis S.,
Sticova E.,
Hulkova H.,
Trhlikova O.,
Sikora J.
Publication year - 2020
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.15930
Subject(s) - hyperpigmentation , medicine , dermis , palladium , population , pathology , dermatology , chemistry , biochemistry , environmental health , catalysis
Background ‘Braun’ is an illegal injectable dihydrocodeinone‐enriched drug mixture of semi‐synthetic opioids. It is prepared by palladium‐catalysed hydrogenation from codeine‐containing tablets. Objective We aimed to characterize the dermatologic consequences of long‐term abuse of ‘Braun’. Methods Skin biopsies of two long‐term ‘Braun’ abusers were evaluated histopathologically, immunohistochemically and ultrastructurally. Palladium skin content was assessed by X‐ray fluorescence (XRF) spectrometry. Results Both patients showed generalized diffuse dark blue–grey hyperpigmentation of the skin. In both, an abnormal population of cells containing intracytoplasmic brownish granular material was identified in the papillary dermis by light microscopy. Electron microscopy revealed a dense and minimally structured material that predominantly accumulated in macrophages, fibroblasts and vascular endothelial cells. XRF analysis confirmed elevated levels of palladium in the patient's skin in comparison to healthy controls. Conclusion Long‐term abuse of palladium‐contaminated dihydrocodeinone (‘Braun’) results in excessive accumulation of granular material in various dermal cell types and causes generalized diffuse skin hyperpigmentation.